Vanda Pharmaceuticals | VNDA - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
AstraZeneca USD 4.81B 894M 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -11.37M 150.72M 2026-06
J&J USD 8.66B 839M 2026-06
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
Merck USD -3.53B 6.95B 2026-03
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -1.33B 535M 2026-03
Novartis USD 3.84B 1.33B 2026-03
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR 837M 1.17B 2026-06
Takeda JPY 162.72B 215.2B 2026-06
Teva Pharmaceutical Industries USD -455M 1.21B 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Veracyte USD 26.52M 3.45M 2026-06